Monthly Archives: May 2015

Biopharmaceutical News Week 21

Acquisitions /mergers/joint-ventures Endo acquires Par Pharmaceuticals for $8.05 Billion Endo International (Dublin, Ireland) acquires privately-owned Par Pharmaceuticals (Woodcliff Lake, NJ, USA) for $8.05 billion and extends its generics footprint. The deal is structured through a $6.50 billion payment in cash and around $1.55 billion in equity. The deal comes a few month after Endo withdrew its […]

read more

Biopharmaceutical News Week 19-20

Acquisitions /mergers/joint-ventures Alexion acquires Synageva for $8.4 Bn and expands in rare-disease market Alexion Pharmaceuticals (Cheshire, CT, USA) buys Synageva BioPharma (Lexington, MA, USA) for $8.4 billion, at twice its current value, to expand its activities in drugs for rare diseases.  The purchase of Synageva gives Alexion access to its lead product Kanuma (sebelipase alpha) […]

read more

Biopharmaceutical News Week 18

Acquisitions /mergers/joint-ventures The saga Mylan, Teva, Perrigo goes on As expected, Mylan’s board has rejected Teva’s takeover offer of $40 billion indicating that the “proposal grossly undervalues the company” and that it would not even enter any discussions regarding an offer unless the starting point was “significantly in excess of $100 per share”. But at […]

read more